Navigation Links
Clinical Data Demonstrates That LYSTEDA™ Significantly Reduced Menstrual Blood Loss and Limitations on Social, Leisure and Physical Activities in Women With Cyclic HMB
Date:5/19/2010

SAN FRANCISCO, May 19 /PRNewswire/ -- Five presentations reporting the results of two placebo-controlled clinical trials evaluating Ferring Pharmaceuticals' LYSTEDA™ (tranexamic acid) tablets, a novel, first-in-class, non-hormonal therapy indicated for treatment of women with cyclic heavy menstrual bleeding (HMB), were presented at The American College of Obstetricians and Gynecologists 58th Annual Clinical Meeting in San Francisco, May 15-19, 2010.  It is estimated that up to 22 million women suffer from HMB in the U.S.(1),(2)

(Logo:  http://www.newscom.com/cgi-bin/prnh/20100510/NY01272LOGO )

LYSTEDA oral tablets received approval on November 13, 2009 following a Priority Review by the U.S. Food and Drug Administration (FDA).  Ferring recently signed an agreement with Xanodyne Pharmaceuticals, Inc. that will expand its Women's Health product portfolio with the acquisition of the global rights to LYSTEDA, which the company will initially market in the U.S.

"We are extremely pleased by the substantial clinical evidence supporting LYSTEDA as a new therapy for heavy menstrual bleeding.  LYSTEDA was shown to significantly reduce menstrual blood loss in women suffering from cyclic heavy menstrual bleeding," said Andrea Lukes, MD, lead study investigator, Carolina Women's Research and Wellness Center.  "As a result of taking this new treatment, most women in the trial said they experienced a significant, meaningful improvement in their social, leisure and physical activities."

Edward A. Trott, MD, Vice President of Medical Affairs, Ferring Pharmaceuticals, stated, "Heavy menstrual bleeding has long been a widely overlooked and unmet medical need that many women considered normal and did not require special medication.  With the introduction of LYSTEDA, obstetricians and gynecologists can now offer appropriate patients the only non-hormonal therapy that is FDA approved for cyclic heavy menstrual bleeding and taken only during the menstrual phase."

The following results of the oral tranexamic acid formulation (LYSTEDA) were reported from two multicenter, double-blind, placebo-controlled, parallel-group trials of women aged 18-49 years with HMB, defined as mean menstrual blood loss (MBL) greater than 80 mL per cycle, averaged over two cycles and measured by a validated alkaline hematin method.

Dose-Response Analysis

To assess the efficacy and safety of two dosage regimens, 294 women with HMB were randomized (2:2:1) to receive LYSTEDA 1.95 (n=115) or 3.9 g/day (n=112) or placebo (n=67) for up to five days of menstrual bleeding.  MBL was measured during 2 baseline and 3 treatment cycles using a validated alkaline hematin method.  The tripartite primary efficacy endpoint was achieved if MBL reduction from baseline was significantly greater than placebo, met a "meaningful" reduction in MBL threshold of 36 mL/cycle as perceived by women with HMB, and exceeded 50 mL/cycle.

Only women receiving LYSTEDA 3.9 g/day achieved the tripartite endpoint.  Mean reduction of MBL for the 3.9 g/day group was -65.3 mL/cycle compared with -3.0 mL/cycle for women receiving placebo (P<.001).  Both doses of LYSTEDA were well tolerated.

A Meaningful Reduction in MBL

To quantify 'meaningful' reduction in MBL in women with HMB after treatment with LYSTEDA, data from 294 women in the study were used in a blinded receiver operating characteristic (ROC) analysis.  MBL was measured in two ways during the study.  One measured the blood loss using a validated alkaline hematin method at baseline and after treatment with LYSTEDA. The second measured a meaningful reduction in MBL using the Menorrhagia Impact Questionnaire (MIQ), a patient-reported outcome instrument previously validated in an HMB population.  Women in this study were asked if the change in their period after treatment was 'meaningful or important' after treatment compared to their prior pretreatment cycles.  After treatment with LYSTEDA, women with HMB perceived an MBL reduction of 36 mL or greater to be meaningful.  

Effect of LYSTEDA Treatment on Social, Leisure and Physical Activities

To measure changes in social, leisure and physical activities in women with HMB treated with LYSTEDA, women (n=294) were randomized (2:2:1) to receive LYSTEDA 1.95 g/day (n=115), LYSTEDA 3.9 g/day (n=112), or placebo (n=67) for up to five days per menstrual period for three cycles.  The MIQ was used to measure changes at baseline and after three treatment menstrual cycles.  The questionnaire contains questions about limitations on social, leisure, physical, or work activities during menstruation, and the woman's perception of the influence of MBL on those measures.  Women receiving either dose of LYSTEDA experienced significant improvements in all measurements from baseline compared with placebo (P <.01 for each dose).  Improvement in all measurements was greater in women receiving high-dose LYSTEDA compared with low-dose LYSTEDA.  Both dosage regimens were well tolerated.

Effects of BMI, Age and Fibroids on MBL Reduction

Additional post hoc subgroup analyses were conducted using data from a randomized study of 187 women with HMB (LYSTEDA 3.9 g/day (n=115) or placebo (n=72)).  Results showed that LYSTEDA 3.9 g/day significantly and uniformly reduced MBL, regardless of age, the presence of uterine fibroids, baseline MBL or body mass index (BMI).  

About LYSTEDA

LYSTEDA™ (tranexamic acid) tablets are indicated for the treatment of cyclic heavy menstrual bleeding.  Prior to prescribing LYSTEDA, exclude endometrial pathology that can be associated with heavy menstrual bleeding.  For more information, visit www.lysteda.com.

Important Safety Information

LYSTEDA is contraindicated in women with active thromboembolic disease or a history or intrinsic risk of thrombosis or thromboembolism, including retinal vein or artery occlusion; or known hypersensitivity to tranexamic acid.

Concomitant therapy with hormonal contraceptives may further increase the risk of blood clots, stroke, and myocardial infarction.  Women using hormonal contraception should use LYSTEDA only if there is a strong medical need and the benefit of treatment will outweigh the potential increased risk of a thrombotic event.  In case of severe allergic reaction, discontinue LYSTEDA and seek immediate medical attention.  Visual or ocular adverse effects may occur with LYSTEDA.  Immediately discontinue use if visual or ocular symptoms occur.  Concomitant use of LYSTEDA with Factor IX complex concentrates, anti-inhibitor coagulant concentrates or all-trans retinoic acids (oral tretinoin) may increase risk of thrombosis.  Cerebral edema and cerebral infarction may be caused by use of LYSTEDA in women with subarachnoid hemorrhage.

The most common adverse reactions in clinical trials (> 5%, and more frequent in LYSTEDA subjects compared to placebo subjects) were: headache, sinus and nasal symptoms, back pain, abdominal pain, musculoskeletal pain, joint pain, muscle cramps, migraine, anemia and fatigue.

About Ferring Pharmaceuticals Inc.

Ferring Pharmaceuticals Inc. is a subsidiary of Ferring Pharmaceuticals, a privately owned, international pharmaceutical company.  Ferring Pharmaceuticals offers a line of products in the U.S. market.  They include: BRAVELLE® (urofollitropin for injection, purified), MENOPUR® (menotropins for injection, USP) and REPRONEX® (menotropins for injection, USP), NOVAREL® (chorionic gonadotropin for injection, USP), ENDOMETRIN® (progesterone) Vaginal Insert, 100 mg, FIRMAGON® (degarelix for injection), PROSED® DS (methenamine, phenyl salicylate, methylene blue, benzoic acid, hyoscyamine sulfate), DESMOPRESSIN, and EUFLEXXA® (1% sodium hyaluronate).

Ferring Pharmaceuticals specializes in the research, development and commercialization of compounds in general and pediatric endocrinology, urology, orthopaedics, gastroenterology, obstetrics/gynecology, and infertility.  For more information, call 1-888-FERRING (1-888-337-7464) or visit www.FerringUSA.com.

(1)  U.S. Census Bureau, 2006-2008 American Community Survey. Available at: http://factfinder.census.gov/. Accessed April 7, 2010.

(2)  Tufts Medical Center website. Heavy Menstrual Bleeding. Available at: www.tufts-nemc.org. Accessed April 7, 2010.

Please visit www.Lysteda.com for Full Prescribing Information for LYSTEDA.


'/>"/>
SOURCE Ferring Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Mpex Pharmaceuticals Presents Positive Phase 2 Clinical Trial Results of Aeroquin(TM) (MP-376) Treatment in Cystic Fibrosis Patients
2. ADMIRE-HF Clinical Trial Published in the Journal of the American College of Cardiology
3. ThromboGenics and BioInvent to Receive EUR10 Million Milestone as Partner Roche Begins New Clinical Study with TB-403
4. Omeros Selects Clinical Candidate for MASP-2 Program With Potential Applicability to Multiple Inflammatory Disorders
5. 3M and CitiusTech to Integrate 3M Healthcare Data Dictionary With CitiusTechs BI-Clinical Healthcare Business Intelligence Framework
6. CrystalGenomics Announces Successful Completion of a Phase I SAD Clinical Trial for CG400549, its Novel Antibiotic Candidate
7. Somanetics Corporation Announces 24 Clinical Abstracts on INVOS System Presented at Annual Pediatric Academic Societies National Conference
8. Protege Encore Clinical Trial Evaluates New Investigational Approach For Individuals Recently Diagnosed With Type 1 Diabetes
9. Novocell Becomes ViaCyte, Inc., as it Accelerates Pre-Clinical Development of a Stem Cell Derived Treatment for Diabetes
10. Stereotaxis Updates Progress on Major Clinical Initiative Related to Electrophysiology (EP) Treatment of Ventricular Tachycardia
11. US HIFU Receives Unanimous Approval to Continue the Clinical Investigation of High Intensity Focused Ultrasound (HIFU) for Treatment of Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... New Zealand , May 24, 2016 ... and informatics solutions for the healthcare sector, has been named ... New Zealand Hi-Tech Awards 2016. Dr Bruce ... fantastic acknowledgement for our team.  It,s really good to be ... burden healthcare internationally. Our products are used in 35 countries ...
(Date:5/24/2016)... Los innovadores de COMBO[TM], ... introduce catéteres para la intervención de extremidades inferiores ... global especializada en el suministro de soluciones vasculares ... incluyendo productos para tratar la enfermedad arterial periférica. ... los dispositivos de primera entrada de la compañía ...
(Date:5/23/2016)... , May 23, 2016 ... Handling Equipment Market by Product (Wheelchair, Scooters, Medical ... (Bariatric Care, Critical Care, Wound), Accessories (Lifting, Transfer) ... to 2021", published by MarketsandMarkets, the patient handling ... Billion by 2021 at a CAGR of 10.5% ...
Breaking Medicine Technology:
(Date:5/26/2016)... ... May 26, 2016 , ... On May 23rd during the National ... Science® and international water advocate, was honored by Ashram, Inc. as the world’s foremost ... who knelt on the banks of the Nile to fill their red clay pots ...
(Date:5/26/2016)... ... May 26, 2016 , ... The introduction of our ... PROTECTION TO YOUR HEAD ™”. , “We are proud to introduce Meghan ... football front we have Brian Quick, wide receiver for Los Angeles who was a ...
(Date:5/26/2016)... ... 26, 2016 , ... Metcalf & Associates’ Maureen Metcalf ... experience in leading technology and human resources operations for health care, education, banking, ... be featured on Metcalf’s VoiceAmerica radio show , Innovative Leaders Driving Thriving ...
(Date:5/26/2016)... , ... May 26, 2016 , ... May 2016 – ... so central to popular cosmetic improvement efforts. Record numbers of clients now ask about ... prominent or pouty, says Kally Papantoniou, MD, of Advanced Dermatology P.C. , ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... is happy to announce the launch of its brand equity product, Brandvantage. ... to reflect the dynamic landscape of modern consumer decision-making. The proprietary framework ...
Breaking Medicine News(10 mins):